Drug Science is pleased to welcome three new industry partners to its groundbreaking medical cannabis study, T21 (formerly Project TWENTY21).
They are SOMAí Pharmaceuticals, Blackpoint Biotech and 4Clabs who will be joining long standing partner EthyPharm as collaborators.
Launched in 2019, and now over 4000 patients in, T21 is building the scientific evidence base for the safety and efficacy of Cannabis Based Medicinal Products (CBMPs), with the aim of increasing UK patients’ access to these medicines on the NHS.
The project does this by allowing registered UK patients to access discounted private prescriptions of these legal medicines, which cover a broad range of formulations, including various flowers and oils, as well as divergent routes of administration, which go way beyond vaping, covering capsules, inhalers and sublingual administrations.
Partners will help to ensure the future of the project, allowing patients to continue with their discounted medications, and for scientists to collect important health data on these drugs and their effects. They will also allow T21 to extend its formulary — by adding more cannabis-based medicines and offering more choice to the study’s patients.
Anne Schlag is the acting Chief Executive of Drug Science. She says:
“We’re very happy to be able to continue T21 with our esteemed new and existing partners. Now going into its 5th year, T21 remains essential as a way of allowing UK patients to access discounted CBMPs prescriptions, whilst at the same time, furthering the scientific evidence base on these medicines. We already know that CBMPs can benefit a wide range of conditions – from intractable epilepsy to chronic pain as well as various psychiatric conditions.
It is vital to understand how long lasting these results are, whether they differ between population groups, and which CBMPs are most helpful for which conditions. The continuation of T21 allows us to gain many more of these understandings, which we hope will ultimately lead to widening public access to these life-changing medications via NHS prescriptions.”
Michael Sassano, Founder, Chairman & CEO of SOMAÍ Pharmaceuticals says:
“We are delighted to be joining T21 and support one of the largest global registries on Cannabis Based Medicinal Products. Our goal is to provide access to the most comprehensive range of cannabis products to UK patients and gather real-world evidence on the transformative effects of cannabis-based therapeutics. SOMAÍ Pharmaceuticals aims to provide best-in-class care globally, with entry into the UK as a significant milestone.”
Blackpoint Biotech says:
“We believe the T21 study provides vital research that advances cannabis products as medicines. Consequently we are delighted to be partnering with Drug Science in support of T21 as we seek to improve patient and practitioner experience by offering new means of administration that enable increased accuracy in dosing.”
4C Labs says:
“We are proud to be a part of T21 for 2024. We have hand-picked cultivators for their ability to produce the best value in cannabis-based prescription medicines. And we look forward to serving the doctors and patients who are a part of this very important study.”
Martindale Pharma, part of the Ethypharm Group, says:
“We are delighted to be supporting Drug Science and the T21 observational study. As a company with extensive experience in central nervous system and pain-related conditions we welcome and support the continuation of research looking at improvements in quality of life for people living with complex and often difficult to treat conditions.”
